Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25831640 | 1.00 | SRD5A1 (0.49) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL10024954 | 1.00 | SRD5A1 (0.49) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| Acetic Acid SCHEMBL27787883 | 0.90 | SRD5A1 (0.46) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL12270104 | 0.89 | HTR2C (0.44) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL24593559 | 0.84 | HTR2A (0.64) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL3364642 | 0.84 | HTR2A (0.64) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL13487595 | 0.81 | SRD5A1 (0.47) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL14487997 | 0.79 | KDM1A (0.50) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL413401 | 0.78 | SRD5A1 (0.47) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL3988329 | 0.78 | SRD5A1 (0.46) | SRD5A1HTR2AHTR2CHTR2BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9802938-B2 | Sulfamoylating reagents | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8933225-B2 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353555-A9 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | SRD5A1 41/4885HTR2A 4181/4885HTR2C 3891/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | SRD5A1 4008/4885HTR2A 3362/4885HTR2C 3913/4885 |
| US-20090036678-A1 | Process for the synthesis of E1 activating enzyme inhibitors | SULT1E1, SULT1A1, ALDH18A1 | SRD5A1 41/4885HTR2A 4181/4885HTR2C 3891/4885 |
| US-20150080573-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | SRD5A1 41/4885HTR2A 4181/4885HTR2C 3891/4885 |
| US-20180079755-A1 | PROCESS FOR THE SYNTHESIS OF E1 ACTIVATING ENZYME INHIBITORS | SULT1E1, SULT1A1, ALDH18A1 | SRD5A1 38/4885HTR2A 4150/4885HTR2C 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.